Literature DB >> 3699438

Verapamil as an apparent competitive antagonist of the serotonin receptor of rabbit isolated aorta.

M Auguet, S Delaflotte, F Clostre, F V DeFeudis.   

Abstract

The actions of four Ca2+-antagonists (verapamil, diltiazem, nifedipine and flunarizine) were tested on serotonin- (5-HT-) induced contraction of rabbit isolated aorta. Verapamil produced a dose-dependent, parallel shift to the right of the concentration-response curve for 5-HT (pA2 approximately equal to 7.13; Schild slope approximately equal to 1.01), indicative of competitive antagonism. The effects of diltiazem, nifedipine and flunarizine were much less pronounced and best characterized as non-competitive interactions. The effect of verapamil, which likely involves its antagonism of smooth muscle 5-HT2-receptors, might be useful in explaining its therapeutic actions and/or its side-effects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3699438     DOI: 10.1016/0306-3623(86)90129-1

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  4 in total

1.  Some central pharmacological effects of the calcium channel antagonist flunarizine.

Authors:  A Czyrak; E Mogilnicka; J Maj
Journal:  J Neural Transm Gen Sect       Date:  1991

2.  Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats.

Authors:  F E O'Brien; G Clarke; P Fitzgerald; T G Dinan; B T Griffin; J F Cryan
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

3.  Effects of calcium channel blockers on the contractile response to dihydroergotamine in isolated human femoral veins.

Authors:  E Glusa; F Markwardt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-05       Impact factor: 3.000

4.  Effects of a new calcium antagonist, CD-832, on experimental coronary artery spasm in miniature pigs.

Authors:  T Takahashi; T Fukai; H Hata; H Kasuya; T Kuga; K Egashira; A Takeshita
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.